Vaxcyte (PCVX) Competitors $79.74 -2.73 (-3.31%) Closing price 04:00 PM EasternExtended Trading$80.44 +0.70 (+0.88%) As of 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends PCVX vs. ARGX, BNTX, ONC, TEVA, SMMT, GMAB, ITCI, VTRS, MRNA, and RDYShould you be buying Vaxcyte stock or one of its competitors? The main competitors of Vaxcyte include argenx (ARGX), BioNTech (BNTX), Beigene (ONC), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Intra-Cellular Therapies (ITCI), Viatris (VTRS), Moderna (MRNA), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry. Vaxcyte vs. argenx BioNTech Beigene Teva Pharmaceutical Industries Summit Therapeutics Genmab A/S Intra-Cellular Therapies Viatris Moderna Dr. Reddy's Laboratories Vaxcyte (NASDAQ:PCVX) and argenx (NASDAQ:ARGX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings, media sentiment and community ranking. Is PCVX or ARGX more profitable? Vaxcyte has a net margin of 0.00% compared to argenx's net margin of -2.11%. argenx's return on equity of -1.45% beat Vaxcyte's return on equity.Company Net Margins Return on Equity Return on Assets VaxcyteN/A -23.53% -22.20% argenx -2.11%-1.45%-1.29% Does the media refer more to PCVX or ARGX? In the previous week, argenx had 2 more articles in the media than Vaxcyte. MarketBeat recorded 9 mentions for argenx and 7 mentions for Vaxcyte. argenx's average media sentiment score of 1.22 beat Vaxcyte's score of 1.08 indicating that argenx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive argenx 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer PCVX or ARGX? Vaxcyte presently has a consensus target price of $127.71, indicating a potential upside of 60.16%. argenx has a consensus target price of $658.39, indicating a potential upside of 2.16%. Given Vaxcyte's stronger consensus rating and higher possible upside, analysts clearly believe Vaxcyte is more favorable than argenx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxcyte 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00argenx 1 Sell rating(s) 2 Hold rating(s) 18 Buy rating(s) 1 Strong Buy rating(s) 2.86 Which has more risk & volatility, PCVX or ARGX? Vaxcyte has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500. Comparatively, argenx has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Does the MarketBeat Community believe in PCVX or ARGX? argenx received 601 more outperform votes than Vaxcyte when rated by MarketBeat users. However, 75.41% of users gave Vaxcyte an outperform vote while only 67.19% of users gave argenx an outperform vote. CompanyUnderperformOutperformVaxcyteOutperform Votes4675.41% Underperform Votes1524.59% argenxOutperform Votes64767.19% Underperform Votes31632.81% Which has better valuation & earnings, PCVX or ARGX? argenx has higher revenue and earnings than Vaxcyte. argenx is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxcyteN/AN/A-$402.27M-$4.60-17.33argenx$1.27B30.87-$295.05M-$0.88-732.36 Do insiders & institutionals have more ownership in PCVX or ARGX? 96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 60.3% of argenx shares are owned by institutional investors. 3.1% of Vaxcyte shares are owned by insiders. Comparatively, 2.4% of argenx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Summaryargenx beats Vaxcyte on 10 of the 18 factors compared between the two stocks. Get Vaxcyte News Delivered to You Automatically Sign up to receive the latest news and ratings for PCVX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PCVX vs. The Competition Export to ExcelMetricVaxcyteBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.94B$3.12B$5.78B$8.98BDividend YieldN/A1.57%4.78%3.85%P/E Ratio-17.3330.1126.4618.82Price / SalesN/A412.67457.0180.82Price / CashN/A183.5344.0437.47Price / Book6.123.567.634.64Net Income-$402.27M-$71.72M$3.18B$245.69M7 Day Performance-5.07%-2.45%-1.82%-2.63%1 Month Performance-9.56%0.36%0.22%-2.37%1 Year Performance10.35%-11.50%17.49%13.65% Vaxcyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PCVXVaxcyte2.5867 of 5 stars$79.74-3.3%$127.71+60.2%+11.3%$9.94BN/A-17.33160Insider TradePositive NewsARGXargenx2.5232 of 5 stars$639.41-1.8%$658.39+3.0%+63.8%$38.85B$1.27B-726.601,148News CoveragePositive NewsBNTXBioNTech2.3788 of 5 stars$119.83-2.4%$142.72+19.1%+29.2%$28.73B$4.13B-57.066,133Positive NewsONCBeigeneN/A$230.86+2.4%N/AN/A$22.56B$2.46B-28.0210,600Insider TradeNews CoverageGap UpTEVATeva Pharmaceutical Industries2.8884 of 5 stars$16.24-2.4%$23.57+45.2%+30.1%$18.39B$16.54B-11.2037,851SMMTSummit Therapeutics2.3035 of 5 stars$21.37-2.1%$33.57+57.1%+516.6%$15.76B$700,000.00-76.32110Gap UpGMABGenmab A/S4.5897 of 5 stars$21.30+1.8%$42.17+98.0%-22.5%$14.10B$2.39B20.682,204ITCIIntra-Cellular Therapies3.9113 of 5 stars$127.82-0.2%$103.62-18.9%+74.4%$13.59B$464.37M-146.92560Earnings ReportAnalyst ForecastNews CoverageVTRSViatris2.3252 of 5 stars$10.80flat$13.67+26.5%-16.5%$12.89B$15.43B-14.5938,000News CoverageMRNAModerna4.7389 of 5 stars$32.99+3.4%$66.89+102.8%-61.2%$12.70B$6.85B-5.675,600Analyst DowngradeOptions VolumeHigh Trading VolumeRDYDr. Reddy's Laboratories2.8624 of 5 stars$13.60-2.8%$17.00+25.0%-11.7%$11.35B$311.31B21.6527,048Gap Down Related Companies and Tools Related Companies argenx Competitors BioNTech Competitors Beigene Competitors Teva Pharmaceutical Industries Competitors Summit Therapeutics Competitors Genmab A/S Competitors Intra-Cellular Therapies Competitors Viatris Competitors Moderna Competitors Dr. Reddy's Laboratories Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PCVX) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxcyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxcyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PCVX Stock Alerts